How is the Thyroid Gland Doing After COVID-19 Infection?
New research shows that there is a clear link between thyroid dysfunction and COVID-19 disease through various mechanisms.
Source: medindia.net
📰 About Thyroid News
About Thyroid News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from About Thyroid. Real-time updates on events, politics, business and more.
Exelixis, Inc.: Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
- Approval is based on COSMIC-311 trial, in which CABOMETYX demonstrated significant improvement in progression-free survival versus placebo - Exelixis, Inc. (Nasdaq: EXEL) today announced that
United States Susan Hubbard Vickil Goodman Lindsay Treadway Daiichi Sankyo Company European Commission
Source: finanznachrichten.de
Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
– CHMP recommendation follows September 2021 U.S. FDA approval of CABOMETYX in this setting – ... | March 25, 2022
United States Vickil Goodman Daiichi Sankyo Company European Commission Drug Administration Genentech Inc
Source: marketscreener.com
Exelixis Announces Cabozantinib Significantly Improved Progression-Free Survival in COSMIC-311 Phase 3 Pivotal Trial in Patients with Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer
Published: Dec 21, 2020 ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (NASDAQ: EXEL) today announced that COSMIC-311, the phase 3 pivotal trial evaluating cabozantinib (CABOMETYX ®) versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after up to two prior vascular endothelial growth factor receptor (VEGFR)-targeted therapies, met the co-primary endpoint of demonstrating significant improvement in progression-free survival. Cabozantin...
United States Marcias Brose Gisela Schwab Abramson Cancer Center Takeda Pharmaceutical Company American Thyroid Association
Source: biospace.com